Product Name: LATSSubtide
Product Number: PE-01BHU90
Size: 200 µg      Price:43.00
1 mg      $US85.00
5 mg      201.00
Peptide Name: LATSSubtide

Product Use: For assaying the phosphotransferase activity of Large tumour suppressor 2 protein-serine kinase (UniProt ID Q9NRM7).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KGHFRRKSFRRFG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1853.18 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid
Storage Conditions: -20°C

Peptide Recommended Enzyme: LATS

Scientific Background: LATS2 is a protein-serine/threonine kinase of the AGC group and NDR family. It is involved in cell-cycle regulation and spindle formation. LATS2 is localized to centrosomes during interphase to late metaphase by aurora-A kinase. LATS2 recruits gamma-tubulin for spindle formation. LATS2 may inhibit cell growth during arrest at the G1/S or G2/M check points. LATS2 appears to function primarily as a tumour suppressor protein through activating p53 by physically inhibiting MDM2. Cancer-related mutations in human tumours point to a loss of function of the protein kinase. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. K697A and S872A mutations lead to loss of tumour suppressor activity. Through a positive feedback mechanism p53 can positively regulate expression of LATS2. Abberant expression of LATS2 either through downregulation or hypermethylation has been observed in various cancers including, lung, breast, hepatocellular, leukaemias, testicular, astrocytomas, retinoblastoma and head and neck cancers. S83E and S83C mutations in LATS2 lead to failure to localize at the centromere during interphase. LATS2 deletion in mice was lethal at embryonic states, which indicates that it may have a critical role in maintainance of mitotic fidelity and genomic integrity.